

LAHIVE
&
COCKFIELD
LLP

ATTORNEYS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)
THOMAS V. SMURZYNSKI
RALPH A. LOREN
GIULIO A. DeCONTI, JR.
ANN LAMPORT HAMMITTE
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DeANN FORAN SMITH
PETER C. LAURO
JEANNE M. DIGIORGIO
DEBRA J. MILASINCIC, Ph.D.
DAVID J. RIKKERS
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER

CYNTHIA L. KAN, Ph.D.
MEGAN E. WILLIAMS, Ph.D.
RICHANAND
MICHAEL PHILLIPPS
LISA M. DIROCCO
HATHAWAY P. RUSSELL
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.
PETER A. DIMATTIA
VINCENT P. LOCCISANO
MERIDETH C. ARNOLD

SENIOR COUNSEL
JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
WILLIAM A. SCOFIELD, JR.
SIBLEY P. REPERT

PATENT AGENTS
THEODORE R. WEST
SHAYNE Y. HUFF, Ph.D.
DANIEL B. KO

TECHNICAL SPECIALISTS
CYNTHIA M. SOROOS
PETER W. DINI, Ph.D.
EUIHOON LEE
JENNIFER K. ROSENFELD
ALLAN TAMESHTIT, Ph.D.
CATHERINE E. McPHERSON
ERIC F. WAGNER, Ph.D.
SHAHID HASAN, Ph.D.
JACOB G. WEINTRAUB
JONATHAN M. SPARKS, Ph.D.
CRISTIN E. HOWLEY, Ph.D.

* Admitted in NY only
** Admitted in TX only

165
#6/
I.D.S.

Commissioner for Patents
Washington, D.C. 20231

July 18, 2002

RECEIVED

JUL 26 2002

Re: U.S. Patent Application No.: 10/010408
For: NOVEL HEPARIN-INDUCED CCN-LIKE MOLECULES AND USE
THEREFOR
Inventor: John J. Castellot, Jr.
Filed: December 7, 2001
Our Ref. No.: MBI-004CN

TECH CENTER 1600/2900

COPY OF PAPERS
ORIGINALLY FILED

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement;
2. PTO Form 1449;
3. Copies of selected references cited in PTO Form 1449 (3); and
3. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

Date: 7/18/02

Amy E. Mandragouras, Esq., Reg. No. 36,207

Respectfully submitted,
LAHIVE & COCKFIELD, LLP

Amy E. Mandragouras, Esq.
Registration No. 36,207
Attorney for Applicant



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re ~~the~~ application of: John J. Castellot, Jr.

Serial No.: 10/010408

Filed: December 7, 2001

For: NOVEL HEPARIN-INDUCED CCN-LIKE
MOLECULES AND USE THEREFOR

Attorney Docket No.: MBI-004CN

Group Art Unit: 1633

Examiner: James Martinell

RECEIVED

JUL 26 2002

TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

COPY OF PAPERS
ORIGINALLY FILED

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

7/18/02
Date of Signature and of Mail Deposit

By:

Amy E. Mandragouras, Esq.
Reg. No. 36,207
Attorney for Applicant

INFORMATION DISCLOSURE STATEMENT

Dear Sir:


For the Examiner's convenience in reviewing this continuation application, Applicant submits a consolidated PTO Form 1449, listing all references cited during the prosecution of the parent application. References A1-C20 were previously cited and submitted to the Office in U.S. Application Serial No. 09/044273, filed March 19, 1998 (Atty. Docket No. MBI-004), of which this application is a continuation, and to which this application claims priority. In accordance with 37 CFR §1.98(d), these references are not enclosed herewith, but

will be provided upon request. In addition, this Information Disclosure Statement presents references D1-D3, not previously submitted to the Office, and which are enclosed herewith in accordance with 37 CFR §1.97.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicant understands that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP



Amy E. Mandragouras, Esq.
Registration No. 36,207
Attorney for Applicant

28 State Street
Boston, MA 02109
(617) 227-7400

Date: July 18, 2002

GAD/AEM/SYH/krj